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Lung cancer is still the most common cancer in the world.
Following the steady decline in incidence in men in England and
Wales for over 20 years, it is now the second most common cancer
in men (19000 cases a year, 8% lifetime risk) after prostate cancer,
and it causes 17000 deaths a year. In women, the long-term
increase in incidence has recently flattened off, but lung cancer is
now the third most common cancer (13000 cases a year, 4%
lifetime risk) after cancers of the breast and large bowel, and it
causes 11500 deaths a year (Quinn et al, 2001; Office for National
Statistics, 2005). Lung cancer is the commonest cause of death
from cancer in both men and women.
Most lung cancers are caused by tobacco smoking, and
incidence trends follow the trends of tobacco consumption, with
an approximate 20-year time lag. In turn, mortality trends closely
mirror the lung cancer incidence trends, with very little time lag,
because survival has been so poor for so long. Lung cancer alone
accounts for approximately 5% of all deaths in England and Wales.
Screening has not been shown to reduce mortality. Survival from
lung cancer has not improved much for decades, and even in
European countries with the highest survival, 5-year relative
survival remains less than 15% (Berrino et al, 1995b; Sant et al,
2003).
The most deprived group has a lung cancer incidence almost
double that of the most affluent group, in both men and women
(Quinn et al, 2001). Trends in incidence show a decline of
approximately 20% since the late 1980s in men, and a plateau in
the late 1990s for women: the trends are parallel, affecting all
socioeconomic groups about equally (data not shown).
The survival analyses reported here relate to 392000 patients
diagnosed with a first, primary, invasive malignancy of the trachea,
bronchus or lung in England and Wales during the period 1986–
1999, who were followed up to 31 December 2001, some 79% of the
497000 patients potentially eligible for inclusion. Of these, 1.5%
were excluded because their vital status was unknown at 5
November 2002, when the data were extracted for analysis, and a
further 16% because their survival was unknown (or zero): most of
those were registered solely from a death certificate. A further
16000 (3.2%) patients were excluded because they previously had
cancer in another organ at some time since 1971.
Lung cancers assigned to the upper lobe comprised 23% of
cases in the late 1980s, rising to 29% by the late 1990s, with a
commensurate drop in the proportion with an unspecified lobe of
origin, from 54 to 46%, suggesting improvement in the recording
of pathology rather than changing patterns of disease. The lower
lobe accounted for 12% of cases and the middle lobe 3%, with 8%
assigned to the main bronchus. Bronchus and lung cancers
predominate: those of the trachea accounted for only 0.3% of
cases, unchanged since the 1970s. Approximately 28% were
papillary or squamous carcinomas, 13% small cell or oat cell
carcinomas and 12% adenocarcinomas, but 40% were poorly
specified carcinomas.
SURVIVAL TRENDS
For patients diagnosed during 1996–1999, 1-year survival was
23–24%. This represents a small but statistically significant
increase of 1.3% every 5 years since the late 1980s, after adjustment
for deprivation (Table 1, Figure 1). Relative survival 5 or 10 years
after diagnosis has remained extremely low, however, at 5–6% in
both men and women. These survival rates are unchanged since
the early 1970s (Coleman et al, 1999).
Predictions of survival, derived from patients’ survival
experience during the period 2000–2001 with hybrid analysis
(Brenner and Rachet, 2004), do not suggest any imminent
improvement in 1-year or 5-year survival.
DEPRIVATION
Despite the very low overall survival, a significant socioeconomic
gradient in relative survival is evident in both sexes, with lower
short-term and longer-term survival among the more deprived
groups (Table 2). The fitted difference in 1-year survival between
men in the most affluent and most deprived groups who were
diagnosed during 1996–1999 was 3.4%. There is no evidence of a
significant change in these deprivation gradients in survival
(Table 2, Figure 2).
Short-term predictions from hybrid analysis do not suggest any
imminent change in the socioeconomic gradient in survival.
COMMENT
Survival from lung cancer remains desperately poor, at levels
roughly similar to those for patients diagnosed 30 years ago
(Coleman et al, 1999), although short-term survival may improve
slightly in the near future.
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www.bjcancer.comBias in these survival estimates should be considered. A
substantial minority of cases (16%) had to be excluded from
analysis because the only available information was from a death
certificate, so their duration of survival was unknown. Approxi-
mately half these cases were from the south east (data not shown),
and work elsewhere has shown that they would in fact have had
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 21.3 (21.1, 21.6) 21.2 (20.9, 21.5) 23.2 (22.9, 23.5) 1.3** (0.6, 1.9) 23.0 (22.6, 23.5)
Women 21.0 (20.6, 21.4) 21.5 (21.1, 21.8) 24.1 (23.7, 24.5) 1.3** (0.4, 2.2) 23.8 (23.2, 24.4)
5 years Men 6.0 (5.8, 6.2) 5.4 (5.2, 5.5) 6.0 (5.8, 6.3) 0.1 ( 0.3, 0.5) 6.0 (5.7, 6.3)
Women 5.9 (5.7, 6.2) 5.5 (5.3, 5.7) 6.5 (6.2, 6.8) 0.1 ( 0.5, 0.7) 6.5 (6.1, 6.9)
10 years Men 4.7 (4.5, 4.9) 4.1 (4.0, 4.3)  0.6 ( 1.3, 0.1) 4.7 (4.4, 5.0)
Women 4.5 (4.3, 4.7) 4.0 (3.7, 4.2) 0.2 ( 0.7, 1.2) 4.8 (4.4, 5.1)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival
estimated with cohort or complete approach (1986–1990, 1991–1995,
1996–1999) or hybrid approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival
(%) by sex and calendar period of diagnosis: England and Wales,
adults (15–99 years) diagnosed during 1986–1999 and followed
up to 2001.
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(Berrino et al, 1995a). In other words, the impact of excluding
these death certificate only cases from the analyses would thus be
to bias the survival estimates upwards, and not to reduce them.
One-year survival has nevertheless improved slightly but
steadily during the 1990s. This may reflect the short-term efficacy
of recent chemotherapy protocols for some morphological types of
lung cancer. Another possible explanation is a trend towards
earlier diagnosis. Information on the stage of disease at diagnosis
was not available in these data. The average age of patients fell
slightly during the years 1986–1999, possibly reflecting greater
awareness of lung cancer and earlier diagnosis.
Both explanations may underlie the small but persistent deprivation
gap in survival at 1 year after diagnosis. Compared with more deprived
groups, affluent groups may have taken greater advantage of new
treatments or lung cancer awareness campaigns, both of which may in
turn have had an impact on short-term survival.
In the absence of substantial gains in lung cancer survival in
England and Wales among patients diagnosed during 1986–1999,
it should be noted that 1-year and 5-year survival in both countries
was significantly lower than the average for patients diagnosed
during 1990–1994 in the 22 countries contributing to the
EUROCARE-3 study. After standardisation to a common age
distribution in that study, 5-year lung cancer survival in England
was 7.4% for men and 7.7% for women, compared with the
European average values of 9.7 and 9.6%, respectively (Sant et al,
2003). In England, 1-year survival was 22.7% in both sexes,
compared with European average values of 31.4 and 29.8% in
men and women, respectively. In Wales, 1-year survival was
2–3% lower than in England, but 5-year survival was similar.
Among western and northern European countries, the only
country with lower lung cancer survival than England, Scotland
and Wales was Denmark, where it has been attributed to late stage
at diagnosis (Storm et al, 1999).
The persistent lack of improvement in lung cancer survival
in England and Wales should be a cause for serious concern.
Survival rates have improved in other European countries. Earlier
diagnosis, enabling surgery and radiotherapy of curative intent in
a higher proportion of cases, would appear the most likely
approach to make progress.
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  2.1** ( 2.9,  1.3)  1.1** ( 1.9,  0.3)  3.4** ( 4.4,  2.4)  0.4 ( 1.1, 0.2)  3.2** ( 4.6,  1.8)
Women  1.3*(  2.5,  0.1)  1.9** ( 3.0,  0.7)  0.7 ( 2.0, 0.6) 0.3 ( 0.7, 1.2)  1.2 ( 3.1, 0.6)
5 years Men  0.7** ( 1.2,  0.2)  0.5 ( 1.0, 0.0)  1.4** ( 2.2,  0.7)  0.3 ( 0.7, 0.2)  1.5** ( 2.3,  0.6)
Women  0.9*(  1.6,  0.1)  1.2** ( 1.9,  0.6)  0.6 ( 1.6, 0.3) 0.0 ( 0.6, 0.7)  0.6 ( 1.7, 0.5)
10 years Men  0.4 ( 0.9, 0.1)  0.4 ( 0.9, 0.2) 0.0 ( 0.7, 0.8)  0.9*(  1.8,  0.1)
Women  0.7*(  1.4, 0.0)  1.5** ( 2.2,  0.8)  0.8 ( 1.8, 0.1)  0.9 ( 1.9, 0.2)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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